At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 287 enrolled
Drug / intervention
Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)
In Brief
A Phase 4 clinical trial evaluating Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) for Macular Degeneration. Completed, enrolled 287 participants across 39 sites in 8 countries.
Detailed Summary
This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesAustralia, Canada, France, Germany, Hungary, Italy, Spain, United Kingdom
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionApr 2019
TodayJul 2026
First PostedOct 21, 2015
Enrollment StartNov 19, 2015
Primary CompletionApr 26, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.7 years ago
Interventions
Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)drug
3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)drug
3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria